Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Allergy Immunotherapy Market by Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy) , by Application (Allergy Rhinitis, Asthma, Food Allergy, Others) by Distribution Channel (Hospital Pharmacies, Retail, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033

A10241

Pages: 216

Charts: 59

Tables: 136

Allergy Immunotherapy Market Research, 2033

The global Allergy Immunotherapy Market Size was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033. The allergy immunotherapy market growth is driven by a combination of rising prevalence of allergic disorders and advancements in treatment options. A key driver for this market is the increasing incidence of allergies worldwide. According to the World Health Organization estimates, 1 in 2 people in the world will be suffering from allergies diseases by 2050

Market Introduction and Definition

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment aimed at reducing the sensitivity to allergens. It involves the gradual introduction of increasing amounts of the allergen into the patient's body, typically through injections (subcutaneous immunotherapy) or sublingual tablets or drops (sublingual immunotherapy) . Over time, this process helps the immune system become less reactive to the allergen, thereby reducing the severity and frequency of allergic reactions. This therapy is primarily used to treat conditions such as allergic rhinitis, allergic asthma, and insect venom allergies. It is particularly beneficial for patients who do not respond well to conventional allergy medications. 

Key Takeaways 

  • The allergy immunotherapy market share study covers 20 countries. The research includes a segment analysis of each country in terms of value ($Billion) for the projected 2024-2033 allergy immunotherapy market forecast period. 
  • More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major Allergy Immunotherapy industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights. 
  • The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives. 

 Key Market Segments

  • By Type
    • Subcutaneous Immunotherapy
    • Sublingual Immunotherapy
  • By Application
    • Allergy Rhinitis
    • Asthma
    • Food Allergy
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail
    • Online Pharmacies
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Allovate, LLC
  • HAL Allergy Group
  • Stallergenes Greer
  • Torii Pharmaceutical Co., Ltd.
  • Leti Pharma
  • ALK-Abello A/S
  • Jubliant Pharma
  • Allergy Therapeutics
  • Merck KGaA
  • Biomay AG

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Subcutaneous Immunotherapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Sublingual Immunotherapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Allergy Rhinitis

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Asthma

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Food Allergy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacies

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Allergy Immunotherapy Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Allergy Immunotherapy Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Allergy Immunotherapy Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Allergy Immunotherapy Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Allergy Immunotherapy Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Allergy Immunotherapy Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Allergy Immunotherapy Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Allergy Immunotherapy Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Allergy Immunotherapy Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Allergy Immunotherapy Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Allergy Immunotherapy Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Allergy Immunotherapy Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Allergy Immunotherapy Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Allergy Immunotherapy Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Allergy Immunotherapy Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Allergy Immunotherapy Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Allergy Immunotherapy Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Allergy Immunotherapy Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Allergy Immunotherapy Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Allergy Immunotherapy Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Allergy Immunotherapy Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Allergy Immunotherapy Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Allergy Immunotherapy Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Allergy Immunotherapy Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Allergy Immunotherapy Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Torii Pharmaceutical Co., Ltd.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Biomay AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. ALK-Abello A/S

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Allergy Therapeutics

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Allovate, LLC

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. HAL Allergy Group

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Jubliant Pharma

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Leti Pharma

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Merck KGaA

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Stallergenes Greer

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGY RHINITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ASTHMA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR FOOD ALLERGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 18. U.S. ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. U.S. ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 21. CANADA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 22. CANADA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. CANADA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE ALLERGY IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 37. ITALY ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ITALY ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. ITALY ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 43. UK ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. UK ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. UK ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 56. CHINA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. CHINA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. CHINA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 62. INDIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. INDIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. INDIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA ALLERGY IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 96. UAE ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 97. UAE ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 98. UAE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 105. TORII PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 106. TORII PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 107. TORII PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 108. TORII PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 109. TORII PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BIOMAY AG: KEY EXECUTIVES
  • TABLE 111. BIOMAY AG: COMPANY SNAPSHOT
  • TABLE 112. BIOMAY AG: OPERATING SEGMENTS
  • TABLE 113. BIOMAY AG: PRODUCT PORTFOLIO
  • TABLE 114. BIOMAY AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ALK-ABELLO A/S: KEY EXECUTIVES
  • TABLE 116. ALK-ABELLO A/S: COMPANY SNAPSHOT
  • TABLE 117. ALK-ABELLO A/S: OPERATING SEGMENTS
  • TABLE 118. ALK-ABELLO A/S: PRODUCT PORTFOLIO
  • TABLE 119. ALK-ABELLO A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. ALLERGY THERAPEUTICS: KEY EXECUTIVES
  • TABLE 121. ALLERGY THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 122. ALLERGY THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 123. ALLERGY THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 124. ALLERGY THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. ALLOVATE, LLC: KEY EXECUTIVES
  • TABLE 126. ALLOVATE, LLC: COMPANY SNAPSHOT
  • TABLE 127. ALLOVATE, LLC: OPERATING SEGMENTS
  • TABLE 128. ALLOVATE, LLC: PRODUCT PORTFOLIO
  • TABLE 129. ALLOVATE, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. HAL ALLERGY GROUP: KEY EXECUTIVES
  • TABLE 131. HAL ALLERGY GROUP: COMPANY SNAPSHOT
  • TABLE 132. HAL ALLERGY GROUP: OPERATING SEGMENTS
  • TABLE 133. HAL ALLERGY GROUP: PRODUCT PORTFOLIO
  • TABLE 134. HAL ALLERGY GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. JUBLIANT PHARMA: KEY EXECUTIVES
  • TABLE 136. JUBLIANT PHARMA: COMPANY SNAPSHOT
  • TABLE 137. JUBLIANT PHARMA: OPERATING SEGMENTS
  • TABLE 138. JUBLIANT PHARMA: PRODUCT PORTFOLIO
  • TABLE 139. JUBLIANT PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. LETI PHARMA: KEY EXECUTIVES
  • TABLE 141. LETI PHARMA: COMPANY SNAPSHOT
  • TABLE 142. LETI PHARMA: OPERATING SEGMENTS
  • TABLE 143. LETI PHARMA: PRODUCT PORTFOLIO
  • TABLE 144. LETI PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. MERCK KGAA: KEY EXECUTIVES
  • TABLE 146. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 147. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 148. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 149. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. STALLERGENES GREER: KEY EXECUTIVES
  • TABLE 151. STALLERGENES GREER: COMPANY SNAPSHOT
  • TABLE 152. STALLERGENES GREER: OPERATING SEGMENTS
  • TABLE 153. STALLERGENES GREER: PRODUCT PORTFOLIO
  • TABLE 154. STALLERGENES GREER: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 3. SEGMENTATION ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 11. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGY RHINITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ALLERGY IMMUNOTHERAPY MARKET FOR ASTHMA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ALLERGY IMMUNOTHERAPY MARKET FOR FOOD ALLERGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 20. ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. TORII PHARMACEUTICAL CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. TORII PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. TORII PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. BIOMAY AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. BIOMAY AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. BIOMAY AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. ALK-ABELLO A/S: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ALK-ABELLO A/S: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ALK-ABELLO A/S: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ALLERGY THERAPEUTICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ALLERGY THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ALLERGY THERAPEUTICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. ALLOVATE, LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. ALLOVATE, LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. ALLOVATE, LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. HAL ALLERGY GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. HAL ALLERGY GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. HAL ALLERGY GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. JUBLIANT PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. JUBLIANT PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. JUBLIANT PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. LETI PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. LETI PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. LETI PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. MERCK KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. MERCK KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. STALLERGENES GREER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. STALLERGENES GREER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. STALLERGENES GREER: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Allergy Immunotherapy Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved